Insider Selling: Encompass Health Co. (NYSE:EHC) CFO Sells 12,260 Shares of Stock

Encompass Health Co. (NYSE:EHC - Get Free Report) CFO Douglas E. Coltharp sold 12,260 shares of the stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $86.34, for a total value of $1,058,528.40. Following the transaction, the chief financial officer now directly owns 136,227 shares of the company's stock, valued at $11,761,839.18. The sale was disclosed in a filing with the SEC, which is available at this link.

Encompass Health Price Performance

NYSE:EHC traded down $0.08 during trading hours on Wednesday, reaching $86.94. 280,851 shares of the company traded hands, compared to its average volume of 657,265. The firm's 50-day moving average is $86.61 and its 200-day moving average is $81.92. The stock has a market cap of $8.75 billion, a P/E ratio of 23.50, a P/E/G ratio of 1.45 and a beta of 0.89. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.37 and a quick ratio of 1.37. Encompass Health Co. has a 1-year low of $57.55 and a 1-year high of $94.38.

Encompass Health (NYSE:EHC - Get Free Report) last announced its earnings results on Monday, August 5th. The company reported $1.11 EPS for the quarter, beating analysts' consensus estimates of $1.01 by $0.10. The firm had revenue of $1.30 billion for the quarter, compared to analysts' expectations of $1.30 billion. Encompass Health had a return on equity of 18.01% and a net margin of 7.60%. Encompass Health's quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.95 EPS. Equities research analysts expect that Encompass Health Co. will post 4.09 earnings per share for the current fiscal year.

Encompass Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Tuesday, October 1st will be issued a dividend of $0.17 per share. This is a boost from Encompass Health's previous quarterly dividend of $0.15. The ex-dividend date of this dividend is Tuesday, October 1st. This represents a $0.68 annualized dividend and a dividend yield of 0.78%. Encompass Health's dividend payout ratio (DPR) is 18.38%.

Institutional Investors Weigh In On Encompass Health

Hedge funds have recently made changes to their positions in the business. Jackson Creek Investment Advisors LLC boosted its holdings in shares of Encompass Health by 364.4% during the fourth quarter. Jackson Creek Investment Advisors LLC now owns 13,910 shares of the company's stock worth $928,000 after purchasing an additional 10,915 shares during the last quarter. Trillium Asset Management LLC acquired a new stake in shares of Encompass Health during the first quarter worth $4,432,000. TD Asset Management Inc boosted its holdings in shares of Encompass Health by 16.0% during the first quarter. TD Asset Management Inc now owns 2,283,674 shares of the company's stock worth $188,586,000 after purchasing an additional 314,488 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Encompass Health by 2.3% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,318,784 shares of the company's stock worth $87,989,000 after purchasing an additional 29,926 shares during the last quarter. Finally, Harbor Capital Advisors Inc. boosted its holdings in shares of Encompass Health by 275.7% during the second quarter. Harbor Capital Advisors Inc. now owns 35,799 shares of the company's stock worth $3,071,000 after purchasing an additional 26,270 shares during the last quarter. Institutional investors and hedge funds own 97.25% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Mizuho increased their target price on Encompass Health from $93.00 to $95.00 and gave the stock a "buy" rating in a research note on Thursday, April 25th. Truist Financial increased their target price on Encompass Health from $95.00 to $100.00 and gave the stock a "buy" rating in a research note on Monday, July 15th. Stephens reaffirmed an "overweight" rating and issued a $105.00 price objective on shares of Encompass Health in a research note on Tuesday, August 6th. Raymond James reaffirmed a "strong-buy" rating and issued a $95.00 price objective (up from $85.00) on shares of Encompass Health in a research note on Friday, April 26th. Finally, UBS Group raised their price objective on Encompass Health from $96.00 to $100.00 and gave the company a "buy" rating in a research note on Thursday, August 8th. Nine research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Encompass Health has an average rating of "Buy" and an average target price of $99.88.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.